Developments in cytotoxic chemotherapy: advances in treatment utilising vinorelbine (Q34460671)

2 August 2017

1 reference

title

Developments in cytotoxic chemotherapy: advances in treatment utilising vinorelbine (English)

1 reference

2 August 2017

0 references

1 reference

Aapro MS

1

1 reference

2 August 2017

Harper P

series ordinal

2

1 reference

2 August 2017

Johnson SA

series ordinal

3

1 reference

2 August 2017

Vermorken JB

series ordinal

4

1 reference

2 August 2017

publication date

1 December 2001

1 reference

Critical Reviews in Oncology Hematology

2 August 2017

published in

1 reference

2 August 2017

volume

40

1 reference

2 August 2017

issue

3

1 reference

2 August 2017

page(s)

251-263

1 reference

Phase I pharmacologic study of a new Vinca alkaloid: navelbine

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Antiproliferative activity of vinorelbine (Navelbine) against six human melanoma cell lines.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubules

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Effects of vinorelbine on epidermal growth factor-receptor binding of human breast cancer cell lines in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Vinblastine-induced phosphorylation of Bcl-2 and Bcl-XL is mediated by JNK and occurs in parallel with inactivation of the Raf-1/MEK/ERK cascade

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Vinorelbine induces apoptosis and caspase-3 (CPP32) expression in leukemia and lymphoma cells: a comparison with vincristine

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

In vitro synergy of paclitaxel (Taxol) and vinorelbine (navelbine) against human melanoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Vinorelbine tartrate and paclitaxel combinations: enhanced activity against in vivo P388 murine leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Severe neurotoxicity from vinorelbine-paclitaxel combinations

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Vinorelbine chemotherapy in non small cell lung cancer: experience in elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Randomized study of vinorelbine (VRB) versus vindesine (VDS) in previously untreated stage IIIB or IV non-small-cell lung cancer (NSCLC). The Japan Vinorelbine Lung Cancer Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Long term analysis of survival in the European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

The cost-effectiveness of navelbine alone or in combination with cisplatin in comparison to other chemotherapy regimens and best supportive care in stage IV non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Multicenter randomized clinical trial on high-dose epirubicin plus cis-platinum versus vinorelbine plus cis-platinum in advanced non small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Cisplatin and vinorelbine followed by ifosfamide plus epirubicin vs the opposite sequence in advanced unresectable stage III and metastatic stage IV non-small-cell lung cancer: a prospective randomized study of the Southern Italy Oncology Group (GOI

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Carboplatin and vinorelbine in the treatment of advanced non-small-cell lung cancer: a multicenter phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Carboplatin and vinorelbine in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Phase I study of vinorelbine and ifosfamide in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Treatment of stage III-IV non-small-cell lung carcinoma with vinorelbine in combination with ifosfamide plus MESNA: a study by the Southern Italy Oncology Group (GOIM).

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Vinorelbine and ifosfamide for unresectable non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Ifosfamide and vinorelbine as first-line chemotherapy for advanced non-small cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

A phase II study of docetaxel and vinorelbine combination chemotherapy in patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Phase II study of vinorelbine and gemcitabine for inoperable stage IIIB-IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Phase II study of vinorelbine/ifosfamide/cisplatin for the treatment of advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Vinorelbine, ifosfamide and cisplatin in advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Cisplatin, ifosfamide, and vinorelbine combination chemotherapy in stage III-IV non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Phase I/II study of vinorelbine, mitomycin, and cisplatin for stage IIIB or IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Mitomycin C, vinorelbine, carboplatin plus granulocyte-macrophage colony-stimulating factor for treatment of advanced non-small cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Multicenter randomized trial comparing cisplatin-mitomycin-vinorelbine versus cisplatin-mitomycin-vindesine in advanced non-small cell lung cancer. 'Groupe Français de Pneumo-Cancérologie'

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Combination chemotherapy with docetaxel, vinorelbine and cisplatin as first-line treatment of advanced non-small-cell lung cancer: a multicenter phase II study of the Greek Cooperative Group for Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

The multifractionated, twice-weekly dose schedule for a three-drug chemotherapy regimen: a phase I-II study of paclitaxel, cisplatin, and vinorelbine

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Cisplatin, gemcitabine and vinorelbine in locally advanced or metastatic non-small-cell lung cancer: a phase I study.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: a phase II randomized study of the Southern Italy Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Onc

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

A phase I-II study of paclitaxel, ifosfamide, and vinorelbine with filgrastim (rhG-CSF) support in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

A phase I/II trial of neoadjuvant chemotherapy with cisplatin and vinorelbine followed by accelerated irradiation for patients with inoperable nonsmall cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Accelerated split-course (type B) thoracic radiation therapy plus vinorelbine/carboplatin combination chemotherapy in stage III inoperable non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Phase I study of vinorelbine, cisplatin, and concomitant thoracic radiation in the treatment of advanced chest malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Vinorelbine as first-line chemotherapy for metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

A prospective, randomized Phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Vinorelbine and epirubicin in metastatic breast cancer. A dose finding study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Epirubicin/vinorelbine as first line therapy in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

A dose finding study for the combination of epidoxorubicin and vinorelbine, delivered every two weeks with G-CSF support, in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: A high-activity, dose-dense weekly regimen for advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

A phase I/II study of vinorelbine, doxorubicin, and methotrexate with leucovorin rescue as first-line treatment for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

A phase I trial of vinorelbine in combination with mitoxantrone in patients with refractory solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

First-line vinorelbine-mitoxantrone combination in metastatic breast cancer patients relapsing after an adjuvant anthracycline regimen: results of a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Phase I-II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer: a regimen with a low subjective toxic burden

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Effective treatment of advanced breast cancer with vinorelbine, 5-fluorouracil and l-leucovorin plus human granulocyte colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Five-day infusion fluorouracil plus vinorelbine i.v. in metastatic pretreated breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Treatment with a nonanthracycline regimen in advanced breast cancer: vinorelbine, cyclophosphamide, and 5-fluorouracil with folinic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Phase II study of vinorelbine and ifosfamide in anthtracycline resistent metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: a phase I-II clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Vinorelbine and mitomycin C in anthracycline-pretreated patients with advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Effective treatment of advanced breast cancer with vinorelbine, mitomycin C plus human granulocyte colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

A phase II trial of vinorelbine and thiotepa in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Combination cisplatin-vinorelbine for relapsed and chemotherapy-pretreated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Phase I/II study of paclitaxel and vinorelbine in metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Paclitaxel plus vinorelbine: an active regimen in metastatic breast cancer patients with prior anthracycline exposure.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Paclitaxel and vinorelbine in anthracycline-pretreated breast cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Infusional paclitaxel and weekly vinorelbine chemotherapy with concurrent filgrastim for metastatic breast cancer: high complete response rate in a phase I-II study of doxorubicin-treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Vinorelbine and paclitaxel as first-line chemotherapy in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

A phase II trial of intravenous vinorelbine in previously untreated patients with extensive small cell lung cancer, a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Carboplatin plus vinorelbine, a new well-tolerated and active regimen for the treatment of extensive-stage small-cell lung cancer: a phase II study. Gruppo Oncologico Centro-Sud-Isole

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Phase II study of vinorelbine in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: an EORTC Gynaecological Cancer Cooperative Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Vinorelbine as neoadjuvant chemotherapy in advanced cervical carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Phase II study of cisplatin and vinorelbine as first-line chemotherapy in patients with carcinoma of the uterine cervix

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Vinorelbine in pre-treated advanced head & neck squamous cell carcinoma. A phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

A phase II trial of vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil: a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Vinorelbine, cisplatin, and 5-fluorouracil as initial treatment for previously untreated, unresectable squamous cell carcinoma of the head and neck: results of a phase II multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Vinorelbine, bleomycin and methotrexate as a salvage therapy for patients with head and neck squamous carcinoma in relapse after cisplatin/fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Vinorelbine and carboplatin in recurrent and/or metastatic squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Vinorelbine in the treatment of lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900167-6

7 January 2021

10.1016/S1040-8428(01)00167-6

Identifiers

DOI

1 reference

2 August 2017

1 reference